Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes (Q45238112)

11 December 2017

Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes (English)

1 reference

11 December 2017

1 reference

Alan F List

1

1 reference

11 December 2017

1 October 2008

1 reference

11 December 2017

1 reference

11 December 2017

15 Suppl

1 reference

11 December 2017

29-39

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

11 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

T cell‐mediated inhibition of erythropoiesis in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Lenalidomide: an immunomodulatory drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801504S04

10.1177/107327480801504S04

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference

PubMed ID

18813207